All Stories

Alnylam's move into ATTR-CM with Amvuttra is a 'category growth story,' CEO says

After BridgeBio's ATTR-CM drug Attruby blew away analyst projections on Wednesday, Alnylam countered with positive news as well for its Amvuttra.

May 1, 2025 - 16:56
 0
Alnylam's move into ATTR-CM with Amvuttra is a 'category growth story,' CEO says
After BridgeBio's ATTR-CM drug Attruby blew away analyst projections on Wednesday, Alnylam countered with positive news as well for its Amvuttra.
Read More

Tags:

Previous Article

Ads-Tec Energy secures up to $50 million of gross proceeds to accelerate interna...

Next Article

PSE&G open to utility-owned generation to tackle supply needs: CEO LaRossa

Related Posts

Bausch Health, after setting up 'poison pill' defense, reveals activist investor Carl Icahn's 34% interest

Bausch Health, after setting up 'poison pill' defense, ...

Apr 22, 2025  0

Regulatory tracker: AbbVie's Rinvoq scores 9th FDA nod, this time in GCA

Regulatory tracker: AbbVie's Rinvoq scores 9th FDA nod,...

May 1, 2025  0

Sanofi nets €10B from Opella stake sale, eyes more 'bolt-on' deals

Sanofi nets €10B from Opella stake sale, eyes more 'bol...

Apr 30, 2025  0